Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide

Lupoli, Gelsy Arianna; Cascone, Edvige; Arlotta, Francesco; Vitale, Giovanni; Celentano, Luigi; Salvatore, Marco; Lombardi, Gaetano

doi:10.1002/(sici)1097-0142(19960901)78:5<1114::aid-cncr23>3.0.co;2-4

Cited by 66 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, the response to the therapy of bone metastases through surgery (Schlumberger, 1998), radioiodine (Marcocci et al, 1989;Maxon and Smith, 1990;Proye et al, 1992), external irradiation (Tubiana et al, 1985), chemotherapy (Grebe and Hay, 1995;Schlumberger, 1998) and biological therapy (Lupoli et al, 1996;Vitale et al, 2000) is poor in thyroid cancer patients.…”

mentioning

confidence: 99%

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

et al. 2001

View full text Add to dashboard Cite

Summary Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment. Bone destruction in skeletal metastases results from osteoclast-induced bone resorption. Therefore, a new approach in the therapy of bone metastases consists in using aminobisphosphonates, such as pamidronate, which are potent inhibitors of osteoclastic activity. In the present study, 10 thyroid cancer patients with painful osteolytic bone metastases were administered pamidronate (90 mg, as a 2 hour intravenous infusion) monthly for 12 consecutive cycles. Bone pain, quality of life, performance status, analgesic consumption and disease staging were evaluated before and during the trial. The patients who had been administered pamidronate showed a significant decrease in bone pain (P = 0.0052). Performance status improved nearly significantly (P = 0.051), while the quality of life showed a remarkable amelioration. However, no significant decrease in analgesic consumption was recorded. Partial radiographic response of bone lesions was observed in 2/10 patients. The side effects of pamidronate were mild and transient. In conclusion, monthly infusion of pamidronate is a well-tolerated treatment that induces significant relief from bone pain and improves the quality of life of thyroid cancer patients with symptomatic and osteolytic bone metastases.

show abstract

mentioning

confidence: 99%

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Radiotherapy and chemotherapy play a marginal role in advanced MTC (Vitale et al 2001. Somatostatin analogues are able to control the neuroendocrine symptoms induced by advanced MTC (Lupoli et al 1996, Vitale et al 2000. In recent years, several tyrosine kinase inhibitors (axitinib, cabozantinib, gefitinib, imatinib, motesanib, sorafenib, sunitinib and vandetanib) have been evaluated in phase I, II and III clinical trials of patients with advanced MTC.…”

Section: :1mentioning

confidence: 99%

Animal models of medullary thyroid cancer: state of the art and view to the future

Mantovani

Gaudenzi

Circelli

et al. 2017

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10% of thyroid cancers. Increased understanding of diseasespecific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance. 24:1

show abstract

“…In patients with advanced metastatic disease, the administration of octreotide combined with interferon was studied; in a study of 8 patients with advanced MTC, patients received octreotide (at a starting dose of 150g/day sc for 6 months, followed by a dose of 300g/day sc for another 6 months) combined with rIFN-alpha-2b (at a dose of 5 million IU/day im 3 times a week, for 12 months) (Lupoli et al, 1996); while significant symptomatic improvement was observed in some of the treated patients (diarrhoea, in four patients, and flushing, in one), no significant changes in the size of metastases were observed. A maximum decrease of calcitonin was reached after 3 months in 4 patients, while in all patients the CEA levels decreased during treatment.…”

Section: Page 19 Of 43mentioning

confidence: 99%

The role of somatostatin analogues in the treatment of neuroendocrine tumours

Grozinsky‐Glasberg

Grossman

Korbonits

2008

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide

Abstract: The combination of octreotide and interferon is well tolerated and can be recommended for the treatment of advanced MTC.

Cited by 66 publications

References 28 publications

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

Animal models of medullary thyroid cancer: state of the art and view to the future

The role of somatostatin analogues in the treatment of neuroendocrine tumours

Contact Info

Product

Resources

About